Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$201.42 USD

201.42
2,159,573

+0.95 (0.47%)

Updated Nov 5, 2024 02:27 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Is AbbVie (ABBV) a Solid Growth Stock? 3 Reasons to Think " Yes "

AbbVie (ABBV) possesses solid growth attributes, which could help it handily outperform the market.

Top Ranked Growth Stocks to Buy for November 1st

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, November 1st

Christopher Vargas headshot

AbbVie (ABBV) Set to Report Q3 Results: Can Things Turnaround?

AbbVie (ABBV) is set to report its third quarter results before the opening bell on Friday, November 1.

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Imbruvica to Offset Humira Woes in AbbVie (ABBV) Q3 Earnings?

Rising competition in international markets for Humira might have hurt AbbVie's (ABBV) top line in the third quarter. However, strong growth of Imbruvica is expected to have offset the loss.

What's in the Cards for AbbVie (ABBV) This Earnings Season?

AbbVie's (ABBV) Q3 sales may have been weighed down by biosimilar competition for Humira in international markets. However, strong growth of oncology drugs might have offset impact of Humira's international sales erosion.

AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen (BIIB) Beats on Q3 Earnings, Eyes FDA Nod for Aducanumab

Biogen (BIIB) beats estimates for both earnings and sales in the third quarter. It is set to pursue FDA approval of aducanumab. Shares skyrocket in pre-market trading.

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

AbbVie (ABBV) closed at $77.31 in the latest trading session, marking a +1.11% move from the prior day.

Sweta Killa headshot

What's in Store for Healthcare ETFs in Q3 Earnings?

With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.

AstraZeneca's Breast Cancer Candidate BLA Gets Priority Review

AstraZeneca (AZN) announces acceptance of BLA seeking approval for trastuzumab deruxtecan in metastatic breast cancer by the FDA. The FDA also grants priority review.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow

FDA approves Lilly's (LLY) lasmiditan oral tablets to treat acute migraine. J&J (JNJ) beats earnings and sales estimates in Q3

Novartis' Jakavi Meets Primary Goal in Phase III for GVHD

Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.

Top Ranked Income Stocks to Buy for October 17th

Here are four stocks with buy rank and strong income characteristics for investors to consider today, October 17th.

Is AbbVie (ABBV) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here is Why Growth Investors Should Buy AbbVie (ABBV) Now

AbbVie (ABBV) possesses solid growth attributes, which could help it handily outperform the market.

Top Ranked Momentum Stocks to Buy for October 16th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 16th.

Reata Successfully Completes Neuromuscular Disorder Study

Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.

Kinjel Shah headshot

Allergan (AGN) Shareholders Approve Acquisition by AbbVie

Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.

J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View

J&J (JNJ) comes up with encouraging third-quarter 2019 results.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $73.76, moving +0.18% from the previous trading session.

This is Why AbbVie (ABBV) is a Great Dividend Stock

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector

J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.

Top Ranked Income Stocks to Buy for October 10th

Here are four stocks with buy rank and strong income characteristics for investors to consider today, October 10th.

J&J Ordered by Philadelphia Jury to Pay $8B in Risperdal Case

Philadelphia jury orders J&J (JNJ) to pay punitive damages of $8 billion to a man who claims that the use of Risperdal caused him to develop breasts.